Mainz Biomed N.V., a molecular genetics diagnostic company focused on early cancer detection, announced that its pancreatic cancer project will receive public funding from the Investitions- und ...

Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of ...

Mainz Biomed announced a follow-on offering of 2 million units, raising approximately $4 million for cancer detection initiatives.

BERKELEY, US and MAINZ, Germany – April 29, 2025 – Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of ...

Mainz Biomed executed an $8.0 Million follow-on offering for 1,367,521 units sold at an offering price of $5.85 per unit, priced at-the-market under Nasdaq rules.

Mainz Biomed and Thermo Fisher Scientific signed a collaboration agreement for the development of the Company’s next generation colorectal cancer (CRC) screening product for global markets. The ...

During 2024, Mainz Biomed’s revenue from sales through its lab partner network increased by 33% year over year; this increase was tempered by a decrease in direct-to-consumer sales as the Company ...

Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for faster, accurate results.

Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future ...

Mainz Biomed Announces Stock Split BERKELEY, US and MAINZ, Germany – November 29, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company ...

Mainz Biomed BV shares have tumbled to a 52-week low, touching down at $0.21, as the market responded to a challenging year for the biotechnology firm.